Subtype
Biliary Tract Carcinoma
CI-CAN-00001970Explore in graph →
238 active trials3 approved drugs29 evidence items
- NCIt
- C156781
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001970Explore in graph →
Clinical trials
823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (111)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06567600 | Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma | not yet recruiting | Phase 2 | 43 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06434493 | Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma(EMPHATIC) | not yet recruiting | N/A | 30 | The Christie NHS Foundation TrustOTHER | 0 | Aug 21, 2024 |
| clinicaltrials |
| NCT02989857 | Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)(ClarIDHy) | completed | Phase 3 | 187 | Institut de Recherches Internationales ServierOTHER | 6 | Aug 20, 2024 | clinicaltrials |
| NCT04067960 | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer | completed | Early Phase 1 | 197 | Mayo ClinicOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06530823 | Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma | not yet recruiting | Phase 2 | 38 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Jul 31, 2024 | clinicaltrials |
| NCT06505486 | GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC | unknown | — | 21 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT05009953 | Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer | terminated | Phase 2 | 17 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 11, 2024 | clinicaltrials |
| NCT06490198 | Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin | not yet recruiting | Phase 1 | 30 | Chang Gung Memorial HospitalOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06298968 | Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 38 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04919642 | Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma | completed | Phase 2 | 55 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05518071 | FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1(FLUOPANC) | completed | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT04340986 | Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma(CHC/CC) | recruiting | — | 1,250 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06463548 | Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma | not yet recruiting | N/A | 30 | Yunpeng LiuOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT04584775 | Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care | withdrawn | N/A | 0 | Medical University of GrazOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT04256980 | Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement | completed | Phase 2 | 34 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT06417606 | Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 20 | Zhiyong HuangOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT03337087 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | unknown | Phase 1 / Phase 2 | 18 | Academic and Community Cancer Research UnitedOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT03773302 | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations | terminated | Phase 3 | 48 | QED Therapeutics, a BridgeBio companyINDUSTRY | 15 | May 8, 2024 | clinicaltrials |
| NCT04088188 | Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma | terminated | Phase 1 | 8 | Academic and Community Cancer Research UnitedOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT02452970 | RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy(EPIC) | terminated | Phase 2 | 4 | EpicentRx, Inc.INDUSTRY | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06375642 | A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06296563 | Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC | recruiting | Phase 2 | 20 | Lei ZHAOOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06369480 | Prognostic Factors for Survival in Patients With Cholangiocarcinoma | unknown | — | 2,000 | Rigshospitalet, DenmarkOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06369896 | Digital Single-operator Cholangioscopy and Intraductal Ultrasound for Nonicteric Biliary Strictures(Spy+IDUS) | not yet recruiting | — | 36 | Soonchunhyang University HospitalOTHER | 0 | Apr 17, 2024 | clinicaltrials |
| NCT06370013 | Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors | available | — | — | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06363123 | Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis | unknown | — | 2,700 | Beijing Friendship HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05187312 | Registry for Advanced Endoscopy(ERDB) | recruiting | — | 1,000 | Region StockholmOTHER_GOV | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05714124 | Liver Embolization Approaches for Tumor Management(LEATUM) | recruiting | — | 580 | IRCCS San RaffaeleOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05519605 | Bile Duct Drainage After ERCP Failure: EUS-BD vs PTBD(BESTDRAIN) | unknown | — | 61 | Radboud University Medical CenterOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06357117 | Extent of Intrahepatic Infiltration of Perihilar Cholangiocarcinoma | completed | — | 62 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT03201458 | Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer | completed | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06335927 | HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC | unknown | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT04059562 | Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma(TRITICC) | completed | Phase 2 | 28 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT03339843 | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib(MiMe-A) | completed | Phase 2 | 85 | Jules Bordet InstituteOTHER | 2 | Mar 15, 2024 | clinicaltrials |
| NCT06313554 | Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma | not yet recruiting | N/A | 63 | Fudan UniversityOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06304766 | Open Versus Laparoscopic Ablation of Liver Malignancies(OPTIMAL) | unknown | N/A | 80 | Rigshospitalet, DenmarkOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT05872867 | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | unknown | Phase 1 | 54 | Wellmarker BioINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT05222854 | Comprehensive Genomic Profiling Combined With Real Life Data of "The German-Registry of Incidental Gallbladder Carcinoma" | active not recruiting | — | 200 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05124002 | Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 66 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05292443 | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer | withdrawn | — | 0 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06258824 | MicroRNAs as Bile-based Biomarkers in Pancreaticobiliary Cancers(MIRABILE) | completed | — | 229 | Imperial College LondonOTHER | 1 | Feb 14, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 22, 2024source: clinicaltrials